Dateline City:
KENILWORTH, N.J.
KEYTRUDA is the First Immunotherapy to Show Improved Overall Survival Compared With Chemotherapy in Urothelial Cancer
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the phase 3 KEYNOTE-045 trial investigating the use
of KEYTRUDA (pembrolizumab), the companys anti-PD-1
therapy, in patients with previously treated advanced urothelial cancer,
met the primary endpoint of overall survival (OS). In this trial,
KEYTRUDA was superior compared to investigator choice chemotherapy.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558Courtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more